Internal Medicine, Hematology & Oncology · Houston, TX
NPI
1851512842
Since 2007
Specialty
Internal Medicine, Hematology & Oncology
Code 207RH0003X
Group practices
1
Medicare group memberships
Hospitals
3
Hospital affiliations
6400 Fannin St Ste 2900
Houston, TX, 77030
Phone (713) 704-3961
Groups this clinician bills Medicare through
Medicare paid, 2024
$21K
262 services
Medicare patients, 2024
106
Average age 72
Drug cost, 2024
$2.7M
956 prescriptions
Company payments, 2025
$157
From 9 companies
Procedures and visits billed to Original Medicare, 2024
In 2024, the most common Medicare service billed by Julie H Rowe was code 99214 (office e&m - established), 130 times for 56 patients. In total Julie H Rowe billed 262 services in 14 codes, and Medicare paid $21K.
| Code |
|---|
Official US government data: the national provider registry and Medicare enrollment records, linked by NPI. Last update of this record: 2022-04-11.
| Setting |
|---|
| Services |
|---|
| Patients |
|---|
| Paid per service |
|---|
| Medicare paid |
|---|
| 99214 Office E&M - Established | Office | 130 | 56 | $71.91 | $9,349 |
| 99215 Office E&M - Established | Office | 26 | 20 | $108.01 | $2,808 |
| 99443 Telephone Services | Office | 24 | 20 | $71.33 | $1,712 |
| 99232 Hospital E&M - Subsequent | Facility | 21 | 14 | $63.09 | $1,325 |
| 99223 Hospital E&M - Initial | Facility | 18 | 18 | $138.55 | $2,494 |
| G2211 Visit complexity inherent to evaluation and management associated with medical care services that serve as the continuing focal point for all needed health care services and/or with medical care services that are part of ongoing care related to a patient's | Office | 15 | 11 | $13.15 | $197 |
By year: 2022 $26K for 308 services; 2023 $28K for 318 services; 2024 $21K for 262 services.
Medicare prescription drug claims, 2024
In 2024, the drug Julie H Rowe prescribed most often to Medicare patients was Lenvima (Lenvatinib Mesylate), with 61 prescriptions and refills. In total Julie H Rowe wrote 956 Medicare prescriptions that cost $2.7M.
| Drug | Claims | 30-day fills | Patients | Cost |
|---|---|---|---|---|
| Lenvima Lenvatinib Mesylate | 61 | 61 | 12 | $1.5M |
| Hydrocodone-Acetaminophen Hydrocodone/Acetaminophen | 54 | 54 | 18 | $1,601 |
| Levothyroxine Sodium Generic | 44 | 106 | 19 | $661 |
| Prochlorperazine Maleate Generic | 40 | 42 | 27 | $936 |
| Ondansetron Hcl Generic | 37 | 41 | 27 | $4,798 |
| Pantoprazole Sodium Generic | 35 | 95 | 11 | $741 |
| Eliquis Apixaban | 31 | 33 | Under 11 | $19K |
| Creon Lipase/Protease/Amylase | 27 | 30 | Under 11 | $84K |
| Gabapentin Generic | 26 | 51 | 11 | $504 |
| Mirtazapine Generic | 23 | 61 | 14 | $729 |
| Stivarga Regorafenib | 23 | 26 | Under 11 | $482K |
| Tamsulosin Hcl Generic | 22 | 42 | Under 11 | $360 |
| Spironolactone Generic | 21 | 53 | Under 11 | $312 |
| Amlodipine Besylate Generic | 20 | 56 | Under 11 | $129 |
| Diphenoxylate-Atropine Diphenoxylate Hcl/Atropine | 20 | 20 | 11 | $484 |
Brand drugs: 265 claims; generic drugs: 691 claims; opioid claims: 92.
Money and other things of value reported by the companies
In 2025, drug and medical device companies paid Julie H Rowe $157 ($157 in general payments such as food, travel and fees) from 9 companies. The largest payer was Tempus AI, Inc with $38.7.
Official US government data on Original Medicare services, Medicare prescription drug plans and the payments drug and device companies must report. Services with fewer than 11 patients and drugs with fewer than 11 claims are not published. Procedure codes are shown by number with their public category.